TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.
Grote I, Bartels S, Kandt L, Bollmann L, Christgen H, Gronewold M, Raap M, Lehmann U, Gluz O, Nitz U, Kuemmel S, Zu Eulenburg C, Braun M, Aktas B, Grischke EM, Schumacher C, Luedtke-Heckenkamp K, Kates R, Wuerstlein R, Graeser M, Harbeck N, Christgen M, Kreipe H.
Grote I, et al. Among authors: zu eulenburg c.
Cancer Med. 2021 Dec;10(23):8581-8594. doi: 10.1002/cam4.4376. Epub 2021 Nov 14.
Cancer Med. 2021.
PMID: 34779146
Free PMC article.